Affinage

E2F7

Transcription factor E2F7 · UniProt Q96AV8

Length
911 aa
Mass
99.9 kDa
Annotated
2026-06-09
100 papers in source corpus 33 papers cited in narrative 33 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

E2F7 is an atypical, DP-independent E2F transcription factor that uses two tandem DNA-binding domains to occupy E2F consensus sites and repress a defined subset of E2F target genes, thereby enforcing cell-cycle arrest and coupling proliferation control to genome maintenance (PMID:14633988, PMID:12893818, PMID:15133492, PMID:22180533). It binds DNA most likely as a homodimer in which the two DBDs mimic an E2F/DP heterodimer, and it can also heterodimerize with E2F8 and E2F1 to compete for and silence shared promoters such as E2F1 itself (PMID:15133492, PMID:18194653, PMID:23853115). Repression is executed by recruiting the co-repressor CtBP through a canonical PIDLS motif together with HDAC activity, remodeling chromatin both at promoters and at sites of DNA damage (PMID:23853115, PMID:23974101, PMID:24955216). E2F7 is a transcriptional effector of p53: upon genotoxic stress and during oncogene-induced senescence, p53 directly induces E2F7, which then represses E2F1, DHFR, RAD51 and other replication and repair genes to halt the cell cycle and restrict homologous recombination (PMID:22802528, PMID:22802529, PMID:30032296, PMID:29590434). Its protein level is tightly cell-cycle-gated, with degradation imposed in G2 by SCF–Cyclin F via a C-terminal CY degron and stability conferred by PRMT1-mediated arginine methylation (PMID:31475738, PMID:40298071), while its activity is governed by nucleocytoplasmic partitioning, where XPO1-dependent export and the cytoplasmic anchor SAPCD2 inactivate E2F7 to derepress oncogenic targets in cancer (PMID:29950445, PMID:35197448). Beyond repression, E2F7 forms an activating complex with HIF1 to stimulate VEGFA and govern vascular and neuronal patterning genes such as NRP1, demonstrating a context-dependent dual transcriptional output (PMID:22903062, PMID:26681691).

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2003 High

    Established that E2F7 is a non-canonical E2F that binds E2F sites without a DP partner and represses, rather than activates, target genes—defining a distinct repressive arm of the E2F family.

    Evidence Ectopic expression, ChIP, reporter assays, nuclear fractionation and proliferation assays in MEFs

    PMID:12893818 PMID:14633988

    Open questions at the time
    • DNA-binding stoichiometry not yet resolved
    • co-repressor machinery not identified
    • subset of targets not defined genome-wide
  2. 2004 High

    Resolved the mechanistic basis of DP-independent binding by showing both DBDs are required and E2F7 likely binds as a homodimer mimicking an E2F/DP heterodimer.

    Evidence Mutational analysis of both DBDs, DNA-binding assays and protein modeling

    PMID:15133492

    Open questions at the time
    • no crystal structure of the DNA-bound homodimer
    • heterodimer partners not yet defined
  3. 2008 High

    Placed E2F7 (with E2F8) genetically upstream of E2F1 in an apoptotic and DNA-damage axis, showing it restrains E2F1/p53 to control survival and proliferation in vivo.

    Evidence Conditional knockout mice, ChIP, genetic epistasis with E2f1/p53, and DNA-damage knockdown in cells

    PMID:18194653 PMID:18202719

    Open questions at the time
    • repression mechanism at E2F1 promoter not yet molecularly defined
    • redundancy split between E2F7 and E2F8 unresolved
  4. 2011 High

    Defined the genome-wide direct target set and cell-cycle timing, showing S-phase-peaking E2F7 represses replication, metabolism and repair genes and triggers S-phase arrest with DNA damage when mistimed.

    Evidence ChIP-seq, inducible overexpression, microarray, flow cytometry and comet assay

    PMID:22180533

    Open questions at the time
    • mechanism of cell-cycle-phase-specific activity not explained
    • co-factors at target promoters not identified
  5. 2012 High

    Identified E2F7 as a direct p53 target that enforces DNA-damage and senescence arrest and cooperates with/compensates for RB, integrating it into tumor-suppressive checkpoint circuitry.

    Evidence ChIP for p53 at E2F7 promoter and E2F7 at targets, knockdown, oncogene-induced senescence models and RB-loss epistasis

    PMID:22802528 PMID:22802529

    Open questions at the time
    • how p53 selects E2F7 among E2F genes unclear
    • kinetics relative to RB pathway not dissected
  6. 2012 High

    Revealed a non-repressive role: E2F7/8 partner with HIF1 to activate VEGFA and drive angiogenesis, establishing dual transcriptional output.

    Evidence Reporter assays, ChIP and vascular knockout phenotypes in zebrafish and mice

    PMID:22903062

    Open questions at the time
    • molecular contacts between E2F7 and HIF1 not mapped
    • determinants of activation vs repression unknown
  7. 2013 High

    Identified CtBP as the obligate co-repressor and extended E2F7 function to a transcription-independent role in DNA repair through chromatin remodeling at lesions.

    Evidence In vitro DNA-binding and Co-IP, CtBP2 knockdown, laser micro-irradiation and HDAC/CtBP recruitment at damage sites

    PMID:23853115 PMID:23974101

    Open questions at the time
    • transcription-independent repair role rests on single-lab abstract-level data
    • HDAC isoform identity not specified
  8. 2014 Medium

    Mapped the CtBP interaction to a canonical PIDLS motif and confirmed CtBP-dependence of repression and DNA-damage function biochemically.

    Evidence MS interactome of CtBP2, Co-IP, PIDLS mutagenesis and functional reporter/proliferation assays

    PMID:24955216

    Open questions at the time
    • single-lab interactome
    • relative contribution of CtBP1 vs CtBP2 not quantified
  9. 2015 High

    Extended the HIF1–E2F7 complex to genome-wide co-regulation including repression of NRP1 controlling neuronal axon guidance, showing developmental reach beyond the cell cycle.

    Evidence ChIP-seq, RNA-seq, reporter assays and in vivo zebrafish knockdown/TALEN editing

    PMID:26681691

    Open questions at the time
    • switch between stimulatory and repressive outputs at HIF1-shared loci not explained
  10. 2016 High

    Showed E2F7 shapes the miRNA landscape, repressing proliferative miRNAs and indirectly tuning let-7 maturation via an E2F/c-MYC/LIN28B axis.

    Evidence Genome-wide RNA-seq, ChIP, reporter and knockdown assays

    PMID:26961310

    Open questions at the time
    • direct vs indirect contributions to let-7 not fully separated
  11. 2018 High

    Demonstrated that nucleocytoplasmic control of E2F7 is a clinically actionable switch: XPO1-dependent export mislocalizes E2F7 in cancer, derepressing oncogenic targets, reversible by selinexor.

    Evidence XPO1 inhibition, fractionation, tumor IHC, SPHK1 ChIP and xenografts in HNSCC

    PMID:29950445

    Open questions at the time
    • signals triggering export not defined
    • generality across tumor types unestablished at the time
  12. 2018 High

    Established E2F7 as a restrictor of homologous recombination via RAD51 repression, modulating chemosensitivity of BRCA2-deficient cells and ICL responses.

    Evidence Knockdown, RAD51 ChIP, HR and replication-fork assays, 53BP1/FANCD2 foci, clonogenic survival

    PMID:29590434 PMID:30032296

    Open questions at the time
    • how E2F7 selects repair genes during the cell cycle vs stress not resolved
  13. 2018 Medium

    Uncovered a nucleolar function: perinucleolar E2F7 represses RNA Pol I rRNA transcription by blocking UBF recruitment, linking it to global protein synthesis.

    Evidence Immunofluorescence localization, rRNA-promoter ChIP and Pol I/protein synthesis assays

    PMID:29760477

    Open questions at the time
    • single-lab, unreplicated
    • mechanism of UBF exclusion not detailed
  14. 2019 High

    Defined the G2-phase degradation mechanism: SCF–Cyclin F binds a C-terminal CY degron to ubiquitinate E2F7, timing its removal to permit DNA-repair gene expression and G2/M progression.

    Evidence Co-IP, CY-motif mutagenesis, cyclin F depletion, ubiquitination assays and live-cell imaging

    PMID:31475738

    Open questions at the time
    • integration with other reported degradation routes not reconciled in corpus
    • phosphorylation requirements for degron recognition not detailed
  15. 2021 Medium

    Showed E2F7 competes with DP1/E2F1 at the KPNA2 promoter and that KPNA2 reciprocally controls E2F7/E2F1 nuclear import, forming a feedback loop on its own localization.

    Evidence ChIP, dimerization/DBD mutagenesis, Co-IP and xenografts

    PMID:30254209

    Open questions at the time
    • single-lab
    • physiological weight of the import feedback loop unquantified
  16. 2022 Medium

    Identified SAPCD2 as a cytoplasmic anchor that binds and sequesters E2F7, complementing the XPO1 export mechanism, with selinexor restoring nuclear E2F7 in neuroblastoma.

    Evidence Co-IP, fractionation, expression profiling, selinexor treatment and xenografts

    PMID:35197448

    Open questions at the time
    • binding interface not mapped
    • selectivity for E2F7 over E2F1 mechanistically unexplained
  17. 2022 Medium

    Reported a non-canonical oncogenic activator role: m6A-stabilized E2F7 cooperates with RUNX1/CBFB to transactivate integrin and NTRK1 genes, indicating context-dependent reversal of E2F7 function.

    Evidence m6A-seq/MeRIP, RIP, integrative ChIP-seq/RNA-seq and Co-IP in NPC

    PMID:37028765

    Open questions at the time
    • single-lab, non-canonical mechanism awaits replication
    • determinants of activator vs repressor switch undefined
  18. 2025 Medium

    Established PRMT1-mediated arginine methylation as a stabilizing post-translational mark that protects E2F7 from degradation and enables E2F7-driven SIRT6 activation against senescence.

    Evidence Co-IP, GST pull-down, ubiquitination assays, ChIP, reporter and SA-β-gal assays

    PMID:40298071

    Open questions at the time
    • methylated residues not specified in corpus
    • interplay with SCF–Cyclin F degradation not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How E2F7 switches between repressor and activator outputs, and how its post-translational state, partner choice and subcellular localization are integrated to select target genes, remains unresolved.
  • no structure of DNA-bound E2F7 complexes
  • rules governing activation vs repression at HIF1- and RUNX1-shared loci unknown
  • unified model linking degradation, methylation and export to target selection lacking

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 5 GO:0003677 DNA binding 4 GO:0098772 molecular function regulator activity 2
Localization
GO:0005634 nucleus 2 GO:0005829 cytosol 2 GO:0005730 nucleolus 1
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1640170 Cell Cycle 3 R-HSA-73894 DNA Repair 2 R-HSA-8953897 Cellular responses to stimuli 2
Partners
CCNFCTBP1CTBP2E2F1E2F8HIF1APRMT1SAPCD2
Complex memberships
E2F7-E2F8 dimerHIF1-E2F7 transcriptional complex

Evidence

Reading pass · 33 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2003 E2F7 contains two DNA-binding domains and binds E2F consensus DNA sites independently of DP co-factors, unlike canonical E2F family members. Ectopic expression of E2F7 suppresses E2F target genes and causes G1 accumulation. E2F7 associates with E2F-regulated promoters in vivo, with increased association during S phase, and represses only a subset of E2F-dependent promoters. Ectopic expression, ChIP, reporter assays, flow cytometry, sequence analysis The EMBO journal High 12893818 14633988
2003 E2F7 protein is localized to the nucleus, associates with DNA E2F recognition sites with high affinity, lacks a dimerization domain, transcriptional activation domain, and retinoblastoma-binding domain. E2F7 blocks E2F-dependent activation of a subset of E2F target genes and reduces cellular proliferation of mouse embryo fibroblasts. Nuclear fractionation/localization, DNA-binding assays, reporter assays, proliferation assays in MEFs The Journal of biological chemistry High 12893818
2004 E2F7 has two separate DNA-binding domains both required for DNA binding, cell cycle delay, and transcriptional modulation. Mutational analysis shows that integrity of both DBDs is necessary. Biochemical and modeling data suggest E2F7 binds DNA most likely as a homodimer, with interactions between the two DBDs mimicking an E2F/DP heterodimer. Mutational analysis of DBDs, DNA-binding assays, protein modeling, cell cycle assays Oncogene High 15133492
2008 E2F7 and E2F8 form homo- and heterodimers that bind E2F target promoters including E2F1. Combined deletion of E2f7 and E2f8 in mice causes massive apoptosis and embryonic lethality by E11.5. Loss of E2F7/8 increases E2F1 and p53 levels; loss of either E2f1 or p53 suppresses the apoptosis in double-mutant embryos, establishing an E2F7/8→E2F1→p53 apoptotic axis. Conditional knockout mice, ChIP, genetic epistasis (triple mutants), immunoblotting Developmental cell High 18194653
2008 E2F7 and E2F8 are induced by DNA-damaging agents and bind the promoter of E2F1 (coexisting in a DNA-binding complex) to repress E2F target genes including E2F1. Depletion of either E2F7 or E2F8 increases E2F1 expression and prevents the cell-cycle effects that occur in response to DNA damage, placing E2F7/8 upstream of E2F1 in the DNA damage response. ChIP, siRNA knockdown, reporter assays, flow cytometry after DNA damage EMBO reports High 18202719
2011 E2F7 is highly expressed during mid-to-late S phase, occupies promoters of G1/S-regulated genes (preferentially binding the TTCCCGCC motif), and directly represses their transcription. ChIP-seq identified 89 direct E2F7 target genes involved in DNA replication, metabolism, and DNA repair. Induction of E2F7 during G0-G1/S causes S-phase arrest and DNA damage, whereas expression during G2/M does not disturb cell cycle progression. ChIP-seq, inducible overexpression, microarray, flow cytometry, comet assay Nucleic acids research High 22180533
2012 In response to DNA damage, p53 directly occupies the E2F7 promoter and transcriptionally up-regulates E2F7. E2F7 in turn occupies the E2F1 and DHFR promoters and represses them; ablation of E2F7 abrogates p53-dependent repression of these targets. This defines a p53→E2F7→E2F1/DHFR repression pathway contributing to DNA damage-induced cell cycle arrest. ChIP, siRNA knockdown, reporter assays, qPCR, proliferation assays after genotoxic stress Genes & development High 22802528
2012 E2F7 is the only E2F transcription factor potently up-regulated during oncogene-induced senescence as a direct p53 transcriptional target. Once induced, E2F7 binds and represses E2F target genes and cooperates with RB to enforce cell cycle arrest. When RB is disrupted, E2F7 is further induced and compensates for loss of RB by repressing mitotic E2F target genes, creating a second checkpoint. Oncogene-induced senescence model, ChIP, shRNA knockdown, epistasis experiments (RB loss), gene expression arrays Genes & development High 22802529
2012 E2F7 and E2F8 form a transcriptional complex with HIF1 to stimulate VEGFA promoter activity independent of canonical E2F binding elements, thereby promoting angiogenesis. Simultaneous deletion of E2F7/8 in zebrafish and mice causes severe vascular defects. Reporter assays, ChIP, genetic knockout in zebrafish and mice, transgenic fluorescent vessel imaging The EMBO journal High 22903062
2013 E2F7 forms a heterodimer with E2F1 through interactions involving the DNA-binding domains. In vitro DNA interaction assays demonstrate both E2F1-E2F7 and E2F7-E2F7 complexes on adjacent E2F-binding sites. E2F7 recruits the co-repressor CtBP, and CtBP2 is essential for E2F7-mediated repression of E2F1 transcription. In vitro DNA-binding assays, Co-IP, reporter assays, siRNA knockdown of CtBP2 The Journal of biological chemistry High 23853115
2013 E2F7 makes a transcription-independent contribution to DNA repair by localizing to and binding damaged DNA, where it recruits CtBP and HDAC to alter the local chromatin environment at DNA lesions. Tumor-derived E2F7 mutant alleles encode proteins with compromised transcription and DNA repair properties. Laser micro-irradiation/live imaging at damage sites, ChIP at damaged DNA, HDAC/CtBP recruitment assays, mutant allele functional analysis Cell cycle (Georgetown, Tex.) Medium 23974101
2014 E2F7 interacts with CtBP1 and CtBP2 through a canonical CtBP-binding motif (PIDLS). CtBP2 proteome analysis confirmed E2F7 as a CtBP2-associated protein. E2F7 represses E2F1 transcription and inhibits cell proliferation in a CtBP-dependent manner; CtBP also participates in E2F7-mediated DNA damage response. Proteomic analysis (MS) of CtBP2-associated proteins, Co-IP, reporter assays, proliferation assays, mutagenesis of PIDLS motif Genes & cancer Medium 24955216
2015 E2F7 and HIF1α form a transcriptional complex that co-regulates a genome-wide network of genes with both stimulatory and repressive functions. The HIF1α-E2F7 complex represses Neuropilin 1 (NRP1) through a 41 bp E2F-binding site hub, and this repression regulates motor neuron axon guidance in vivo in zebrafish. ChIP-seq, genome-wide RNA-seq, in vitro reporter assays, in vivo zebrafish morpholino knockdown, TALEN mutagenesis, in situ hybridization Nucleic acids research High 26681691
2016 E2F7 transcriptionally represses a set of proliferation-promoting microRNAs (miR-25, -26a, -27b, -92a, -7) by antagonizing E2F1-3 at their promoters. Additionally, E2F7 indirectly controls let-7 miRNA processing and maturation through a novel E2F/c-MYC/LIN28B axis, whereby E2F7 and E2F1-3 modulate c-MYC and LIN28B levels. Genome-wide RNA-seq, ChIP, reporter assays, siRNA knockdown, qPCR Nucleic acids research High 26961310
2017 E2F7 binds the p21(CIP1/WAF1) promoter and represses its expression in AML cells, promoting cell cycle progression. Interference with E2F7 expression results in inhibition of c-Myc transcriptional activity and downregulation of the miR-17-92 cluster, which contributes to monocytic differentiation block. ChIP, reporter assays, siRNA knockdown, flow cytometry, differentiation assays Cell death & disease Medium 23096114
2018 E2F7 is subject to XPO1 (exportin 1)-dependent nuclear export and is mislocalized to the cytoplasm in >80% of head and neck squamous cell carcinomas (HNSCC). This cytoplasmic mislocalization causes derepression of the E2F7 target SPHK1, driving anthracycline resistance. Treatment with the XPO1 inhibitor selinexor restores nuclear E2F7 and reverses resistance in xenotransplant models. XPO1 inhibitor treatment, nuclear/cytoplasmic fractionation, IHC of human tumors, ChIP for SPHK1 promoter, xenograft models Science translational medicine High 29950445
2018 E2F7-mediated transcriptional repression of RAD51 modulates chemosensitivity of BRCA2-deficient cells. Loss of E2F7 increases RAD51 expression, enhances homologous recombination DNA repair and replication fork stability in BRCA2-deficient cells, and confers resistance to PARP inhibitors and cisplatin. siRNA/shRNA knockdown, ChIP for RAD51 promoter, HR assay, replication fork assay, cell viability assays Nucleic acids research High 30032296
2018 E2F7 represses the expression of genes involved in DNA repair (including RAD51) both throughout the cell cycle and upon induction of DNA interstrand crosslink lesions. E2F7 knockdown reduces 53BP1 and FANCD2 foci, decreases chromosomal aberrations after ICL-inducing agents (but not ionizing radiation), and enhances clonogenic survival after ICL, establishing E2F7 as a restrictor of homologous recombination via RAD51 repression. siRNA knockdown, immunofluorescence (53BP1/FANCD2 foci), chromosomal aberration analysis, cell-based HR assay, clonogenic survival Nucleic acids research High 29590434
2018 E2F7 localizes to the perinucleolar region and represses RNA Polymerase I (Pol I) transcription of ribosomal rRNA genes. Mechanistically, E2F7 hinders UBF (upstream binding factor) recruitment to the rRNA gene promoter, thereby reducing rRNA gene transcription and compromising global protein synthesis. Subcellular localization (immunofluorescence), ChIP at rRNA gene promoter, Pol I transcription assays, protein synthesis assays Cell death & disease Medium 29760477
2019 E2F7 is targeted for proteasomal degradation by the E3 ubiquitin ligase SCF-Cyclin F during G2 phase. Cyclin F binds via its cyclin domain to a conserved C-terminal CY motif on E2F7. An E2F7 mutant unable to interact with SCF-Cyclin F remains stable during G2. Cyclin F depletion causes atypical-E2F-dependent delay of G2/M transition and reduced expression of DNA repair E2F target genes, impairing efficient DNA repair. Co-IP, CY motif mutagenesis, cyclin F depletion, live-cell imaging, ubiquitination assays, cell cycle analysis The EMBO journal High 31475738
2009 E2F7-mediated suppression of proliferation and apoptosis in keratinocytes acts through E2F1-dependent pathways, whereas E2F7-induced differentiation acts through an E2F1-independent pathway. Inhibition of E2F7 in SCC cells sensitizes them to UV- and doxorubicin-induced apoptosis. Ectopic expression, siRNA knockdown, proliferation/apoptosis assays, differentiation marker assays in primary human keratinocytes Cancer research Medium 19223542
2011 E2F7 binds to a unique binding site between -139 and -119 bp of the Sp1 promoter in differentiating keratinocytes. Knockdown of E2F7 in proliferating keratinocytes leads to derepression of Sp1 expression and induction of the differentiation gene TG1. E2F4 knockdown does not alter Sp1 expression, indicating E2F7-specific regulation. ChIP, transient transfection, shRNA knockdown, reporter assays with deletion mapping The Journal of investigative dermatology Medium 21248772
2015 E2F7 competes with E2F1 for binding at the E2F binding site on the miR-15a/16 host gene DLEU2 promoter. Overexpression of E2F7 represses miR-15a/16, leading to increased Cyclin E1 and Bcl-2 and conferring tamoxifen resistance in breast cancer cells. ChIP at DLEU2 promoter, reporter assays, ectopic E2F7 expression, miRNA quantification, cell viability assays Oncotarget Medium 26397135
2020 E2F7 promotes transcription of EZH2 by binding to its promoter, increasing H3K27me3 levels. EZH2 then recruits H3K27me3 to the PTEN promoter, suppressing PTEN expression and activating the AKT/mTOR signaling pathway in glioblastoma. ChIP, luciferase reporter assay, siRNA/shRNA knockdown, western blot, in vivo xenograft British journal of cancer Medium 32814835
2022 VIRMA mediates m6A methylation of the E2F7 3'-UTR; IGF2BP2 then binds and stabilizes E2F7 mRNA. In NPC, E2F7 functions as an oncogenic transcriptional activator (rather than repressor) and cooperates with CBFB-recruited RUNX1 to transactivate ITGA2, ITGA5, and NTRK1, strengthening Akt signaling. m6A-seq/MeRIP, RIP, integrative high-throughput sequencing (ChIP-seq/RNA-seq), Co-IP, in vitro and in vivo functional assays The Journal of biological chemistry Medium 37028765
2022 SAPCD2 directly binds cytoplasmic E2F7 (but not E2F1), alters E2F7 subcellular distribution, and reduces nuclear E2F7. SAPCD2 knockdown increases nuclear E2F7, affecting expression of cell cycle and chromosome instability genes. The XPO1 inhibitor selinexor induces nuclear accumulation of E2F7 and suppresses neuroblastoma growth. Co-IP (SAPCD2-E2F7 interaction), subcellular fractionation, gene expression analysis, selinexor treatment, in vivo xenograft Cell death & disease Medium 35197448
2022 E2F7 directly suppresses TSC1 gene transcription by binding to its promoter, thereby suppressing mTOR complex 1 and stabilizing HIF-1α, whose downstream gene activation drives mTOR inhibitor resistance in hepatocellular carcinoma under hypoxia. ChIP at TSC1 promoter, reporter assays, western blot, HIF-1α stability assays, in vivo xenograft with sirolimus American journal of transplantation Medium 35729702
2023 E2F7 drives autotaxin (ENPP2) transcription through cooperative binding to two E2F7 sites (promoter -1393 bp and second intron 996 bp). Chromosome conformation capture showed that chromosomal looping brings these two sites together. p53 binding to the first intron of murine Enpp2 disrupts E2F7-mediated looping and represses transcription, but this mechanism does not operate in human carcinoma cells. ChIP, yeast one-hybrid, chromosome immunoprecipitation, chromosome conformation capture (3C), reporter assays, shRNA knockdown FASEB journal Medium 37358838
2025 PRMT1-mediated arginine methylation of E2F7 maintains E2F7 protein stability (preventing its ubiquitination/degradation). E2F7 in turn transcriptionally activates SIRT6 by binding its promoter. This PRMT1→E2F7→SIRT6 axis inhibits vascular smooth muscle cell senescence in aortic dissection. Co-IP, GST pull-down, ChIP, luciferase reporter, ubiquitination assay, senescence-associated β-galactosidase staining FASEB journal Medium 40298071
2021 E2F7 directly binds the promoter of KPNA2 (karyopherin alpha 2) competing against DP1 and blocking E2F1-induced KPNA2 activation. Mutation of E2F7 dimerization residues or E2F1 DNA-binding domain abolishes the suppressive effect. KPNA2 in turn mediates nuclear localization of both E2F1 and E2F7. ChIP, reporter assays, mutagenesis of dimerization residues/DBD, Co-IP, in vivo xenograft Oncogene Medium 30254209
2024 E2F7 transcriptionally represses MYBL2 (in contrast to E2F1 which activates it) in gastric cancer cells, demonstrated by ChIP and luciferase reporter assays. The opposing effects of E2F1 and E2F7 on MYBL2 regulate GC cell proliferation through the PI3K/AKT signaling pathway. Differential nucleocytoplasmic distribution of E2F7 in GC cells has functional relevance. ChIP, dual-luciferase reporter assay, siRNA knockdown, in vitro and ex vivo proliferation assays, fractionation The Journal of biological chemistry Medium 39613162
2025 HuR RNA-binding protein upregulates E2F7 expression by increasing the stability of E2F7 mRNA in multiple myeloma cells. E2F7 knockdown has anti-MM effects in vitro and in vivo; E2F7 overexpression partially rescues cell proliferation inhibition caused by HuR targeting. RNA-seq, RIP (HuR-E2F7 mRNA interaction), shRNA knockdown, ectopic expression, in vivo xenograft Acta pharmacologica Sinica Medium 40133626
2016 Keratinocyte-specific loss of E2F7 and E2F8 results in increased expression of E2F1 upon stress (DNA damage, high confluence), triggering apoptosis. In DMBA/TPA skin carcinogenesis, combined inactivation of E2f7/8 enhances tumorigenesis. Additional loss of E2f1 worsens (not rescues) skin tumorigenesis, indicating that the tumor-promoting effect of E2F7/8 loss is only partially compensated by E2F1-dependent apoptosis. Conditional knockout (keratinocyte-specific), DMBA/TPA carcinogenesis protocol, genetic epistasis (E2f1 deletion), gene expression analysis Oncogene High 27452520

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes. The EMBO journal 225 14633988
2008 Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Developmental cell 182 18194653
2003 Identification and characterization of E2F7, a novel mammalian E2F family member capable of blocking cellular proliferation. The Journal of biological chemistry 179 12893818
2012 E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Genes & development 114 22802528
2008 DNA-damage response control of E2F7 and E2F8. EMBO reports 111 18202719
2012 E2F7 and E2F8 promote angiogenesis through transcriptional activation of VEGFA in cooperation with HIF1. The EMBO journal 107 22903062
2011 E2F7 represses a network of oscillating cell cycle genes to control S-phase progression. Nucleic acids research 105 22180533
2012 The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes & development 104 22802529
2005 E2F-8: an E2F family member with a similar organization of DNA-binding domains to E2F-7. Oncogene 101 15897886
2020 LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. Journal of experimental & clinical cancer research : CR 97 33168027
2020 E2F7-EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression. British journal of cancer 94 32814835
2004 E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene 86 15133492
2018 MicroRNA-30a-5p inhibits gallbladder cancer cell proliferation, migration and metastasis by targeting E2F7. Cell death & disease 83 29540696
2018 SNHG6 functions as a competing endogenous RNA to regulate E2F7 expression by sponging miR-26a-5p in lung adenocarcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 75 30257360
2009 E2F7 can regulate proliferation, differentiation, and apoptotic responses in human keratinocytes: implications for cutaneous squamous cell carcinoma formation. Cancer research 74 19223542
2015 MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7. Oncology reports 67 25708247
2012 The microRNA-26a target E2F7 sustains cell proliferation and inhibits monocytic differentiation of acute myeloid leukemia cells. Cell death & disease 64 23096114
2015 E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. Oncotarget 63 26397135
2018 MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis. Journal of experimental & clinical cancer research : CR 62 30326936
2018 Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells. Nucleic acids research 60 30032296
2016 Synergistic functions of E2F7 and E2F8 are critical to suppress stress-induced skin cancer. Oncogene 56 27452520
2018 E2F1 and E2F7 differentially regulate KPNA2 to promote the development of gallbladder cancer. Oncogene 52 30254209
2016 MiR-129 triggers autophagic flux by regulating a novel Notch-1/ E2F7/Beclin-1 axis to impair the viability of human malignant glioma cells. Oncotarget 48 26824182
2019 Cyclin F-dependent degradation of E2F7 is critical for DNA repair and G2-phase progression. The EMBO journal 46 31475738
2018 An E2F7-dependent transcriptional program modulates DNA damage repair and genomic stability. Nucleic acids research 44 29590434
2018 The protective role of all-transretinoic acid (ATRA) against colorectal cancer development is achieved via increasing miR-3666 expression and decreasing E2F7 expression. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 40 29772445
2018 A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer. International journal of oncology 39 30066905
2008 E2F7 and E2F8 keep the E2F family in balance. Developmental cell 39 18194644
2018 Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas. Science translational medicine 38 29950445
2016 E2F7 regulates transcription and maturation of multiple microRNAs to restrain cell proliferation. Nucleic acids research 38 26961310
2019 Long non-coding RNA DLEU2 promotes the progression of esophageal cancer through miR-30e-5p/E2F7 axis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 37 31884338
2020 MiR-424-5p regulates cell cycle and inhibits proliferation of hepatocellular carcinoma cells by targeting E2F7. PloS one 34 33201900
2018 microRNA-935 is reduced in non-small cell lung cancer tissue, is linked to poor outcome, and acts on signal transduction mediator E2F7 and the AKT pathway. British journal of biomedical science 32 30203720
2013 Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression. The Journal of biological chemistry 32 23853115
2020 Circ-CCS is identified as a cancer-promoting circRNA in lung cancer partly by regulating the miR-383/E2F7 axis. Life sciences 31 33359669
2015 Genome-wide analysis reveals NRP1 as a direct HIF1α-E2F7 target in the regulation of motorneuron guidance in vivo. Nucleic acids research 31 26681691
2021 Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression. Translational lung cancer research 29 33569293
2020 E2F7, regulated by miR‑30c, inhibits apoptosis and promotes cell cycle of prostate cancer cells. Oncology reports 29 32582990
2021 E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice. Hepatology (Baltimore, Md.) 26 32259305
2019 E2F7, EREG, miR-451a and miR-106b-5p are associated with the cervical cancer development. Archives of gynecology and obstetrics 26 30607582
2019 CircPRKCI-miR-545/589-E2F7 axis dysregulation mediates hydrogen peroxide-induced neuronal cell injury. Biochemical and biophysical research communications 26 31053300
2021 E2F7 Transcriptionally Inhibits MicroRNA-199b Expression to Promote USP47, Thereby Enhancing Colon Cancer Tumor Stem Cell Activity and Promoting the Occurrence of Colon Cancer. Frontiers in oncology 23 33489876
2020 miR-129-5p inhibits proliferation, migration, and invasion in rectal adenocarcinoma cells through targeting E2F7. Journal of cellular physiology 23 32052431
2020 Unravelling the Role of miR-20b-5p, CCNB1, HMGA2 and E2F7 in Development and Progression of Non-Small Cell Lung Cancer (NSCLC). Biology 23 32752229
2023 Dexmedetomidine promotes ferroptotic cell death in gastric cancer via hsa_circ_0008035/miR-302a/E2F7 axis. The Kaohsiung journal of medical sciences 22 36718915
2023 VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner. The Journal of biological chemistry 22 37028765
2022 Gastric cancer cell-derived extracellular vesicles elevate E2F7 expression and activate the MAPK/ERK signaling to promote peritoneal metastasis through the delivery of SNHG12. Cell death discovery 21 35383161
2020 LncRNA CASC19 contributed to the progression of pancreatic cancer through modulating miR-148b/E2F7 axis. European review for medical and pharmacological sciences 20 33155202
2019 MicroRNA-30a suppresses papillary thyroid cancer cell proliferation, migration and invasion by directly targeting E2F7. Experimental and therapeutic medicine 18 31258655
2013 E2F-7 couples DNA damage-dependent transcription with the DNA repair process. Cell cycle (Georgetown, Tex.) 18 23974101
2021 microRNA-26a represses pancreatic cancer cell malignant behaviors by targeting E2F7. Discover oncology 17 35201478
2020 Suppression of Circular RNA Hsa_circ_0109320 Attenuates Non-Small Cell Lung Cancer Progression via MiR-595/E2F7 Axis. Medical science monitor : international medical journal of experimental and clinical research 17 32508344
2020 MiR-10b inhibits migration and invasion of pancreatic ductal adenocarcinoma via regulating E2F7. Journal of clinical laboratory analysis 17 32592206
2022 E2F7 enhances hepatocellular carcinoma growth by preserving the SP1/SOX4/Anillin axis via repressing miRNA-383-5p transcription. Molecular carcinogenesis 16 35924788
2021 Long noncoding RNA LINC00284 facilitates cell proliferation in papillary thyroid cancer via impairing miR-3127-5p targeted E2F7 suppression. Cell death discovery 16 34226533
2020 SNHG7 Contributes to the Progression of Non-Small-Cell Lung Cancer via the SNHG7/miR-181a-5p/E2F7 Axis. Cancer management and research 16 32440218
2014 CtBP2 proteome: Role of CtBP in E2F7-mediated repression and cell proliferation. Genes & cancer 16 24955216
2023 Hsa-miR-195-5p Inhibits Autophagy and Gemcitabine Resistance of Lung Adenocarcinoma Cells via E2F7/CEP55. Biochemical genetics 15 36658310
2020 Up-Regulation of miR-26a-5p Inhibits E2F7 to Regulate the Progression of Renal Carcinoma Cells. Cancer management and research 15 33235501
2020 Circ_SATB2 Attenuates the Anti-Tumor Role of Celastrol in Non-Small-Cell Lung Carcinoma Through Targeting miR-33a-5p/E2F7 Axis. OncoTargets and therapy 15 33239891
2022 SAPCD2 promotes neuroblastoma progression by altering the subcellular distribution of E2F7. Cell death & disease 14 35197448
2024 p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme. BMC cancer 13 38454344
2022 E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 13 35729702
2021 LINC00174 Facilitates Proliferation and Migration of Colorectal Cancer Cells via MiR-3127-5p/ E2F7 Axis. Journal of microbiology and biotechnology 13 34226413
2023 Circular RNA hsa_circ_0000519 contributes to angiogenesis and tumor progression in hepatocellular carcinoma through the miR-1296/E2F7 axis. Human cell 12 36627545
2023 Circ_0010235 confers cisplatin resistance in lung cancer by upregulating E2F7 through absorbing miR-379-5p. Thoracic cancer 12 37277864
2024 Integrated analysis reveals critical cisplatin-resistance regulators E2F7 contributed to tumor progression and metastasis in lung adenocarcinoma. Cancer cell international 11 38760774
2011 Loss of E2F7 expression is an early event in squamous differentiation and causes derepression of the key differentiation activator Sp1. The Journal of investigative dermatology 10 21248772
2024 The roles of E2F7 in cancer: Current knowledge and future prospects. Heliyon 8 39108857
2023 Natural compound So-2 suppresses triple-negative breast cancer through inducing ferroptosis via downregulating transcription factor E2F7. Archives of biochemistry and biophysics 8 37481196
2023 CircPOFUT1 fosters colorectal cancer metastasis and chemoresistance via decoying miR-653-5p/E2F7/WDR66 axis and stabilizing BMI1. iScience 8 38230259
2022 Comprehensive analysis to identify the RP11-478C19.2/ E2F7 axis as a novel biomarker for treatment decisions in clear cell renal cell carcinoma. Translational oncology 8 36054996
2024 E2F1 and E2F7 regulate gastric cancer cell proliferation, respectively, through transcriptional activation and transcriptional repression of MYBL2. The Journal of biological chemistry 7 39613162
2022 Dihydroartemisinin ameliorates chronic nonbacterial prostatitis and epithelial cellular inflammation by blocking the E2F7/HIF1α pathway. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 7 35279736
2021 All-Trans Retinoic Acid Enhances Chemosensitivity to 5-FU by Targeting miR-378c/E2F7 Axis in Colorectal Cancer. Journal of oncology 7 34335757
2018 Functional interplay between E2F7 and ribosomal rRNA gene transcription regulates protein synthesis. Cell death & disease 7 29760477
2021 LncRNA SNHG19 Promotes the Development of Non-Small Cell Lung Cancer via Mediating miR-137/E2F7 Axis. Frontiers in oncology 6 33842336
2014 The miR-302 cluster transcriptionally regulated by POUV, SOX and STAT5B controls the undifferentiated state through the post-transcriptional repression of PBX3 and E2F7 in early chick development. Molecular reproduction and development 6 25394196
2025 FOXO1 mediates miR-99a-5p/E2F7 to restrain breast cancer cell proliferation and induce apoptosis. BMC cancer 5 40264026
2023 Adding pieces to the puzzle of differentiated-to-anaplastic thyroid cancer evolution: the oncogene E2F7. Cell death & disease 5 36765037
2019 Retracted Article: Long non-coding RNA NEAT1 accelerates cell progression in cervical cancer by regulating the miR-889-3p/E2F7 axis through the activation of the PI3K/AKT pathway. RSC advances 5 35529988
2025 PRMT1 Upregulates SIRT6 by Enhancing Arginine Methylation of E2F7 to Inhibit Vascular Smooth Muscle Cell Senescence in Aortic Dissection. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 4 40298071
2024 Coptisine-mediated downregulation of E2F7 induces G2/M phase arrest in hepatocellular carcinoma cells through inhibition of E2F4/NFYA/NFYB transcription factors. Chemico-biological interactions 4 38795876
2023 CISD2 transcriptional activated by transcription factor E2F7 promotes the malignant progression of cervical cancer. Journal of molecular histology 4 37615745
2012 The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells. Investigational new drugs 4 23054209
2025 Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma. Acta pharmacologica Sinica 3 40133626
2025 High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Annals of surgical oncology 3 41454190
2024 Transcription factor E2F7 activates PKMYT1 to partially suppress adriamycin sensitivity in gastric cancer through the MAPK signaling pathway. Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 3 38253021
2024 The novel circFKBP8/miR-432-5p/E2F7 cascade functions as a regulatory network in breast cancer. Hereditas 3 39192374
2024 miR-195-5p inhibits cisplatin resistance in lung adenocarcinoma by regulating DNA damage via targeting E2F7. Journal of biochemical and molecular toxicology 3 39415701
2023 E2F7 drives autotaxin/Enpp2 transcription via chromosome looping: Repression by p53 in murine but not in human carcinomas. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 3 37358838
2022 CircLATS2 Regulates miR-520a-3p/E2F7/p-VEGFR2 Signaling Pathway to Promote Hepatocellular Carcinoma Progression and Angiogenesis. Journal of oncology 3 35444695
2022 HOTAIRM1 Maintained the Malignant Phenotype of tMSCs Transformed by GSCs via E2F7 by Binding to FUS. Journal of oncology 3 35586206
2025 E2F7 upregulates MCM4 and fatty acid metabolism to advance lung adenocarcinoma metastasis. Prostaglandins & other lipid mediators 2 40158794
2024 miR-5100 Overexpression Inhibits Prostate Cancer Progression by Inducing Cell Cycle Arrest and Targeting E2F7. Current issues in molecular biology 2 39590378
2023 E2F7/RAD51AP1 Axis Inhibits Endometrial Cancer Sensitivity to 5-FU via the Fatty Acid Metabolic Pathway. Anticancer research 2 37909953
2023 Transcription Factor E2F7 Hampers the Killing Effect of NK Cells against Colorectal Cancer Cells via Activating RAD18 Transcription. Journal of microbiology and biotechnology 2 38073330
2022 MiR-137 targets and regulates E2F7 to suppress progression of glioma cells. Folia neuropathologica 2 36382488
2025 Suppression of pseudogene MT2P1 transcription induced by E2F7 inhibits hepatocellular carcinoma cell proliferation and facilitates apoptosis via preserving its parental gene. Cancer biology & therapy 1 40407049
2022 lncRNA ENST00000585827 Contributes to the Progression of Endometrial Carcinoma via Regulating miR-424/E2F6/E2F7 Axis. Applied biochemistry and biotechnology 1 36525235

Missed literature

Know a paper Affinage missed for E2F7? Flag it for the maintainers and the community.

No submissions yet.